Search

Your search keyword '"Robert, Camille"' showing total 23 results
Start Over Author "Robert, Camille" Search Limiters Peer Reviewed Publication Year Range Last 3 years
23 results on '"Robert, Camille"'

2. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice

Author

Gencay, Yilmaz Emre, Jasinskytė, Džiuginta, Robert, Camille, Semsey, Szabolcs, Martínez, Virginia, Petersen, Anders Østergaard, Brunner, Katja, de Santiago Torio, Ana, Salazar, Alex, Turcu, Iszabela Cristiana, Eriksen, Melissa Kviesgaard, Koval, Lev, Takos, Adam, Pascal, Ricardo, Schou, Thea Staffeldt, Bayer, Lone, Bryde, Tina, Johansen, Katja Chandelle, Bak, Emilie Glad, Smrekar, Frenk, Doyle, Timothy B., Satlin, Michael J., Gram, Aurelie, Carvalho, Joana, Jessen, Lene, Hallström, Björn, Hink, Jonas, Damholt, Birgitte, Troy, Alice, Grove, Mette, Clube, Jasper, Grøndahl, Christian, Haaber, Jakob Krause, van der Helm, Eric, Zdravkovic, Milan, and Sommer, Morten Otto Alexander

Published
2024
Full Text
View/download PDF

11. Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina

Author

Botto, Catherine, primary, Pulman, Juliette, additional, Malki, Hugo, additional, Ren, Duohao, additional, Oudin, Paul, additional, De Cian, Anne, additional, As, Marie, additional, Izabelle, Charlotte, additional, Saubamea, Bruno, additional, Fouquet, Stephane, additional, Robert, Camille, additional, El-Amraoui, Aziz, additional, FISSON, Sylvain, additional, Concordet, Jean-Paul, additional, and Dalkara, Deniz, additional

Published
2023
Full Text
View/download PDF

12. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice

Author

Gencay, Yilmaz Emre, primary, Jasinskytė, Džiuginta, additional, Robert, Camille, additional, Semsey, Szabolcs, additional, Martínez, Virginia, additional, Petersen, Anders Østergaard, additional, Brunner, Katja, additional, de Santiago Torio, Ana, additional, Salazar, Alex, additional, Turcu, Iszabela Cristiana, additional, Eriksen, Melissa Kviesgaard, additional, Koval, Lev, additional, Takos, Adam, additional, Pascal, Ricardo, additional, Schou, Thea Staffeldt, additional, Bayer, Lone, additional, Bryde, Tina, additional, Johansen, Katja Chandelle, additional, Bak, Emilie Glad, additional, Smrekar, Frenk, additional, Doyle, Timothy B., additional, Satlin, Michael J., additional, Gram, Aurelie, additional, Carvalho, Joana, additional, Jessen, Lene, additional, Hallström, Björn, additional, Hink, Jonas, additional, Damholt, Birgitte, additional, Troy, Alice, additional, Grove, Mette, additional, Clube, Jasper, additional, Grøndahl, Christian, additional, Haaber, Jakob Krause, additional, van der Helm, Eric, additional, Zdravkovic, Milan, additional, and Sommer, Morten Otto Alexander, additional

Published
2023
Full Text
View/download PDF

15. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021

Author

Reich, Adam, Reed, Catherine, Schuster, Christopher, Robert, Camille, Treuer, Tamas, and Lubrano, Ennio

Subjects
Dermatology
Abstract

To describe the results of a structured literature review of real-world outcomes with ixekizumab in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). Literature databases, conference proceedings and additional sources were searched for relevant publications. Real-world studies of ≥25 ixekizumab-treated patients with PsO and/or PsA were included. Data on clinical effectiveness, treatment persistence/patterns, economic outcomes, patient-reported outcomes (PROs) and safety were extracted. Fifty-one publications were included. Most studies focused on patients with PsO, and the number of publications with a focus on PROs was low. Studies of treatment patterns found that in general, ixekizumab had similar or better persistence versus other biologics, and rates or risk of switching similar to or less than comparator drugs. Adherence to ixekizumab was high, and patients were less likely to discontinue ixekizumab than other biologics. Ixekizumab was effective in the real world, with a safety profile consistent with that reported in clinical trials. Real-world use of ixekizumab in PsO and PsA is effective and safe, with generally high treatment persistence and adherence. Further work is required to determine the impact of ixekizumab on PROs in PsO, and to gather more data on real-world use of ixekizumab in PsA.

Published
2023
Full Text
View/download PDF

20. Substantial restoration of night vision in adult mice with congenital stationary night blindness

Author

Varin, Juliette, primary, Bouzidi, Nassima, additional, Gauvain, Gregory, additional, Joffrois, Corentin, additional, Desrosiers, Melissa, additional, Robert, Camille, additional, De Sousa Dias, Miguel Miranda, additional, Neuillé, Marion, additional, Michiels, Christelle, additional, Nassisi, Marco, additional, Sahel, José-Alain, additional, Picaud, Serge, additional, Audo, Isabelle, additional, Dalkara, Deniz, additional, and Zeitz, Christina, additional

Published
2021
Full Text
View/download PDF

21. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coliburden in mice

Author

Gencay, Yilmaz Emre, Jasinskytė, Džiuginta, Robert, Camille, Semsey, Szabolcs, Martínez, Virginia, Petersen, Anders Østergaard, Brunner, Katja, de Santiago Torio, Ana, Salazar, Alex, Turcu, Iszabela Cristiana, Eriksen, Melissa Kviesgaard, Koval, Lev, Takos, Adam, Pascal, Ricardo, Schou, Thea Staffeldt, Bayer, Lone, Bryde, Tina, Johansen, Katja Chandelle, Bak, Emilie Glad, Smrekar, Frenk, Doyle, Timothy B., Satlin, Michael J., Gram, Aurelie, Carvalho, Joana, Jessen, Lene, Hallström, Björn, Hink, Jonas, Damholt, Birgitte, Troy, Alice, Grove, Mette, Clube, Jasper, Grøndahl, Christian, Haaber, Jakob Krause, van der Helm, Eric, Zdravkovic, Milan, and Sommer, Morten Otto Alexander

Abstract

Antibiotic treatments have detrimental effects on the microbiome and lead to antibiotic resistance. To develop a phage therapy against a diverse range of clinically relevant Escherichia coli, we screened a library of 162 wild-type (WT) phages, identifying eight phages with broad coverage of E. coli, complementary binding to bacterial surface receptors, and the capability to stably carry inserted cargo. Selected phages were engineered with tail fibers and CRISPR–Cas machinery to specifically target E. coli. We show that engineered phages target bacteria in biofilms, reduce the emergence of phage-tolerant E. coliand out-compete their ancestral WT phages in coculture experiments. A combination of the four most complementary bacteriophages, called SNIPR001, is well tolerated in both mouse models and minipigs and reduces E. coliload in the mouse gut better than its constituent components separately. SNIPR001 is in clinical development to selectively kill E. coli, which may cause fatal infections in hematological cancer patients.

Published
2023
Full Text
View/download PDF

23. Intestinal Ultrasound, Fecal Calprotectin, and Their Combination to Predict Endoscopic Mucosal Healing in Ulcerative Colitis: A Real-Life Cross-Sectional Study.

Author

Yzet C, Meudjo E, Brazier F, Hautefeuille V, Moreau C, Robert C, Decrombecque C, Sarba R, Pichois R, Richard N, Meynier J, and Fumery M

Abstract

Background: The development of noninvasive markers to assess mucosal healing in ulcerative colitis (UC) is essential in the treat-to-target era. The aim of this study was to evaluate the performance of intestinal ultrasound (IUS), fecal calprotectin (FC), and their combination to assess mucosal healing in UC patients., Methods: All consecutive patients between January 2021 and September 2022 with UC who underwent a complete colonoscopy and IUS and/or an FC test within 4 weeks were included in a prospective cohort. Bowel wall thickness (BWT) and the color Doppler signal (CDS) were assessed for each segment. Endoscopic mucosal healing was defined by a Mayo score of 0 to 1., Results: A total of 61 patients were included, of whom 79% showed endoscopic healing (26 Mayo 0 and 11 Mayo 1). Among the patients, 16 (27.6%) of 58 had a BWT <3 mm, and 41 (70.7%) of 58 had no CDS. The sensitivity, specificity, positive predictive value, and negative predictive value of a BWT <3 mm to predict endoscopic mucosal healing were 37%, 77%, 72%, and 44%, respectively. The association of FC <150 µg/g, a BWT <3 mm, and a CDS = 0 increased the specificity and positive predictive value (sensitivity 33%, specificity 94%, positive predictive value 89%, negative predictive value 48%). The combination of a normal IUS, no rectal bleeding, and an FC <172 µg/g identified all patients with mucosal healing., Conclusion: The combination of IUS and FC is effective in identifying mucosal healing in UC. Noninvasive evaluation of mucosal healing is possible for most UC patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results